Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals and Eli Lilly have released baseline data from Instigate, a 24-month study investigating type II diabetes patients prior to starting insulin therapy and over the following two years.
Subscribe to our email newsletter
Findings show that people with type II diabetes in Europe had insulin initiated at a mean HbA1c of 9.6% and more than 12 months prior to initiation the mean HbA1c was 8.3%. The International Diabetes Federation recommends a target HbA1c of 6.5% or less.
The Instigate study is an ongoing prospective observational study to gather data on medications for diabetes, clinical outcomes, health related quality of life and cost and resource use when patients with type II diabetes initiate insulin, in the six months prior to insulin initiation and over the following two years.
Dr Andreas Liebl, medical director of the Center for Diabetes and Metabolism, said: “The issues of when to start, add or switch diabetes therapies is often a difficult decision for physicians and diabetes specialists, and can have considerable influence on patient care and the costs of disease management.”